Posology: Use in adults, including elderly patients: The dose is 1 drop of IZBA eye drops in the conjunctival sac of the affected eye(s) once daily. Optimal effect is obtained if the dose is administered in the evening.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed 1 drop in the affected eye(s) daily.
When substituting another ophthalmic antiglaucoma medicinal product with IZBA eye drops, the other medicinal product should be discontinued and IZBA eye drops should be started the following day.
Use in patients with hepatic or renal impairment: Travoprost 30 μg/ml has not been studied in patients with hepatic or renal impairment. However, travoprost 40 μg/ml has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 ml/min). No dosage adjustment is necessary in these patients (see Pharmacology: Pharmacokinetics under Actions).
Therefore, no need for dose adjustment at the lower concentration of active ingredient is anticipated.
Use in children and adolescents: The safety and efficacy of IZBA eye drops in children and adolescents below the age of 18 years has not been established.
No data are available.
Method of administration: For ocular use.
For patients who wear contact lenses, patients must be instructed to remove contact lenses prior to application of IZBA eye drops and wait at least 15 minutes after instillation of the dose before reinsertion. The patient should remove the protective overwrap immediately prior to initial use.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.
Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.
If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart. Eye ointments should be administered last.